ONEPOINT Launches Next Generation Project Life Cycle Support with Planforge 22
28.2.2023 11:00:00 EET | Business Wire | Press release
ONEPOINT, a Gartner leader in adaptive project management and reporting, today launched its new Planforge platform — the successor to its hybrid PPM software ONEPOINT Projects. The first major release, Planforge 22, focuses on providing next-generation project life cycle support for agile and traditional projects and programs, including a new dynamic project closure process, modernized change requests, vastly enhanced standard reports, and support for RACI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005123/en/
Planforge 22 supports a new dynamic project closure, lessons learned, and more. (Graphic: Business Wire)
"Planforge is our next step in making hybrid PPM more accessible and powerful at the same time," said Gerald Aquila, founder and CEO of ONEPOINT. "By implementing best practices and lessons learned from hundreds of customer projects analyzed by leading PPM consultants, our software has distinctive built-in project management expertise that is unique in the market."
Dynamic Project Closure
Built around an always accessible project closure form, the new dynamic project closure process is the cornerstone of many practical enhancements to the new Planforge platform:
- 1–5-star ratings and comments for overall project success, each objective and KPI
- Post-project phase can be easily planned using to-dos
- Lessons learned can be added at any time
- Redesigned project closure PDF standard report is based on new capabilities
Lessons Learned
Besides playing an essential role in the new project closure process, lessons learned are real lightweight business objects that are fully reportable using Planforge's flexible report wizard.
"This is a major first step to preserving important project know-how and providing transparency and important learnings to all project stakeholders. Learning from past mistakes and applying successes to future projects is becoming a key success factor," stated Dieter Freismuth, CTO of ONEPOINT.
Modernized Change Requests
Another success factor is effective change request management. By completely redesigning the way change requests are entered and displayed in Planforge, ONEPOINT has managed to incorporate latest best practices while simplifying the user interface. ONEPOINT made change requests more dynamic by allowing project managers to delegate ownership and prioritize changes. Additionally, the Planforge platform now includes a built-in, customizable standard report for a change request.
RACI
Other enhancements include support for RACI, enabling project managers to improve their overview of team responsibilities for complex projects and programs.
Availability
Planforge is available for free for up to 4 users both as a cloud service and on-premises. ONEPOINT also provides different plans for extended connectivity, including a bidirectional integration to Atlassian's Jira. Sign up now at www.planforge.io.
About
ONEPOINT Projects empowers teams to make projects work. With its Planforge hybrid PPM software, ONEPOINT simplifies daily project work with a practical approach to project and portfolio management and enterprise agile planning. Recognized as a Gartner APMR leader, ONEPOINT builds on major standards such as IPMA, PMI, PRINCE2, and SAFe, enabling project-driven organizations to increase project and portfolio transparency, reduce time to market, and optimize resource utilization.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005123/en/
Contact information
ONEPOINT Projects GmbH
Kerstin Gaar
press@onepoint-projects.com
www.planforge.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom